Skip to content

Study · Not a test of the peptide alone · 2017

1 result

[GENOMIC VARIABILITY IN PATIENTS WITH DUCTAL FORM OF BREAST CANCER AND THE POSSIBILITY OF CORRECTION THE PEPTIDE BIOREGULATOR AND METAL IONS].

Jokhadze T, Monaselidze J, Nemsadze G, Buadze T, Gaiozishvili M, Lezhava T

Georgian medical news1 Jan 2017

PMID28252435 (opens in a new tab)PepBankPUB-28252435

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Epitalon was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Epitalon.

  1. 01LabNot a test of Epitalon aloneIn vitro (cells)Efficacy outcome

    In lymphocyte cultures of ductal breast cancer patients, the peptide bioregulator (Ala-Glu-Asp-Gly) and nickel ions, used separately and in combination, had a protective effect. The abstract gives no separate peptide result.

    In plain wordsIn lab tests on cultured blood cells, the peptide and nickel ions showed a protective effect. The abstract does not separate the peptide result.

    Peptide
    Epitalon
    Outcome
    Direction not reportedProtective effect on genome instability
    Study

    humann: not reported in source

    Lymphocyte culture of ductal breast cancer patients
    Outcome group
    Genome stability · Cancer

    Source sentences

    Summary
    The agents - peptide bioregulator (Ala-Glu-Asp-Gly) and nickel ions, used in cell culture of ductal breast cancer patients, revealed the protective effect what indicates the prospects to further study for their involving purpose in combined therapy of this form of cancer.
    1 context sentence
    Summary · context
    Level of genome stability (structural aberrations, aneuploidy and fragile sites) was studied in cells of the lymphocyte culture of ductal breast cancer patients (DBC).

    In this study, Epitalon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Epitalon.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.